Literature DB >> 476562

Remission of giant lymph node hyperplasia with anemia after radiotherapy.

D D Weisenburger, R L DeGowin, P Gibson, J O Armitage.   

Abstract

We have described a 51-year-old patient with unresectable mesenteric giant lymph node hyperplasia of the plasma cell type, severe systemic manifestations, and profound anemia. Supression of erythropoiesis may have been related to the presence of a circulating erythropoietic inhibitor produced by the lymphoid tumor. Markedly elevated titers to Epstein-Barr virus capsid antigen suggest that this virus may be important in the etiology of the abnormal lymphoid proliferation. The marked clinical response and decrease in the size of the tumor following irradiation suggests that radiation therapy may be an alternative form of treatment for similar patients with unresectable lesions.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476562     DOI: 10.1002/1097-0142(197908)44:2<457::aid-cncr2820440212>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Giant lymph node hyperplasia of the mediastinum (Castleman's disease).

Authors:  M A Bhatti; J W Ferrante; I Gielchinsky; J C Norman
Journal:  Tex Heart Inst J       Date:  1984-12

Review 2.  Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.

Authors:  Shou-Hui Zhu; Yong-Hua Yu; Yong Zhang; Ju-Jie Sun; Da-Li Han; Jia Li
Journal:  Med Oncol       Date:  2013-02-12       Impact factor: 3.064

3.  Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids.

Authors:  G P Summerfield; W Taylor; A J Bellingham; H J Goldsmith
Journal:  J Clin Pathol       Date:  1983-09       Impact factor: 3.411

Review 4.  Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature.

Authors:  Iris A C de Vries; Marjolein M S van Acht; Thomas B J Demeyere; Marnix L M Lybeert; Jean-Paul de Zoete; Grard A P Nieuwenhuijzen
Journal:  Radiat Oncol       Date:  2010-02-02       Impact factor: 3.481

5.  The clinical spectrum of Castleman's disease.

Authors:  Angela Dispenzieri; James O Armitage; Matt J Loe; Susan M Geyer; Jake Allred; John K Camoriano; David M Menke; Dennis D Weisenburger; Kay Ristow; Ahmet Dogan; Thomas M Habermann
Journal:  Am J Hematol       Date:  2012-07-13       Impact factor: 10.047

6.  Cases report of unicentric Castleman's disease: revisit of radiotherapy role.

Authors:  O Kyu Noh; Sang-Wook Lee; Jae Whan Lee; Sang Yoon Kim; Chung Soo Kim; Eun Kyung Choi; Jong Hoon Kim; Seung Do Ahn
Journal:  Radiat Oncol J       Date:  2013-03-31

7.  [Castleman disease: unusual location of the chest].

Authors:  Fayçal Eloueriachi; Mohammed Caidi; Fouad Zouaidia; Fahd Ouchen; Mehdi Maidi; Hicham Fennane; Mohamed Bouchikh; Abdellah Achir; Abdellatif Benosman
Journal:  Pan Afr Med J       Date:  2012-08-22

8.  Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature.

Authors:  Chance Matthiesen; Rajeev Ramgopol; Jonathan Seavey; Salahuddin Ahmad; Terence Herman
Journal:  Radiol Oncol       Date:  2012-01-02       Impact factor: 2.991

9.  Castleman disease.

Authors:  Ibrahiem Saeed-Abdul-Rahman; Ali M Al-Amri
Journal:  Korean J Hematol       Date:  2012-09-25

Review 10.  Castleman's disease in the head of the pancreas: report of a rare clinical entity and current perspective on diagnosis, treatment, and outcome.

Authors:  Hongbei Wang; Rosemary L Wieczorek; Michael E Zenilman; Fidelina Desoto-Lapaix; Bimal C Ghosh; Wilbur B Bowne
Journal:  World J Surg Oncol       Date:  2007-11-20       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.